LEADER 01000naa a22002652 4500
001 NLM23246832X
003 DE-627
005 20231224093041.0
007 cr uuu---uuuuu
008 231224s2013 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2013.09.008  |2 doi 
028 5 2 |a pubmed24n0775.xml 
035 |a (DE-627)NLM23246832X 
035 |a (NLM)24211714 
035 |a (PII)S1521-6616(13)00245-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Pandolfi, Julieta  |e verfasserin  |4 aut 
245 1 0 |a Regulatory and effector T-cells are differentially modulated by Dexamethasone 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.12.2013 
500 |a Date Revised 03.12.2013 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2013. 
520 |a It is assumed that the ratio between effector T cells (Teff) and regulatory T cells (Tregs) controls the immune reactivity within the T-cell compartment. The purpose of this study was to investigate if Dexamethasone (Dex) affects Teff and Tregs subsets. Dex induced on Tregs a dose and time-dependent apoptosis which resulted in a relative increase of Teff. After TCR activation, Dex induced a strong proliferative inhibition of Teff, but a weaker proliferative inhibition on Tregs. These effects were modulated by IL-2, which not only restored the proliferative response, but also prevented Dex-induced apoptosis. The highest dose of IL-2 prevented apoptosis on all FOXP3+CD4+ T cells. Meanwhile, the lowest dose only rescued activated Tregs (aTregs), probably related to their CD25 higher expression. Because Dex did not affect the suppressor capacity of aTregs either, our results support the notion that under Dex treatment, the regulatory T-cell compartment maintains its homeostasis 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a APCs 
650 4 |a Apoptosis 
650 4 |a Cytokines 
650 4 |a Dex 
650 4 |a Dexamethasone 
650 4 |a Effector T cells 
650 4 |a GC 
650 4 |a GR 
650 4 |a Glucocorticoids 
650 4 |a Regulatory T cells 
650 4 |a Teff 
650 4 |a Tregs 
650 4 |a aTregs 
650 4 |a activated Tregs 
650 4 |a antigen presenting cells 
650 4 |a effector T cells 
650 4 |a geoMFI 
650 4 |a geometric mean fluorescence intensity 
650 4 |a glucocorticoid receptor 
650 4 |a glucocorticoids 
650 4 |a rTregs 
650 4 |a regulatory T cells 
650 4 |a resting Tregs 
650 7 |a Anti-Inflammatory Agents  |2 NLM 
650 7 |a FOXP3 protein, human  |2 NLM 
650 7 |a Forkhead Transcription Factors  |2 NLM 
650 7 |a IL2RA protein, human  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Interleukin-2 Receptor alpha Subunit  |2 NLM 
650 7 |a Dexamethasone  |2 NLM 
650 7 |a 7S5I7G3JQL  |2 NLM 
700 1 |a Baz, Plácida  |e verfasserin  |4 aut 
700 1 |a Fernández, Pablo  |e verfasserin  |4 aut 
700 1 |a Discianni Lupi, Ailén  |e verfasserin  |4 aut 
700 1 |a Payaslián, Florencia  |e verfasserin  |4 aut 
700 1 |a Billordo, Luis Ariel  |e verfasserin  |4 aut 
700 1 |a Fainboim, Leonardo  |e verfasserin  |4 aut 
700 1 |a Arruvito, Lourdes  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 149(2013), 3 vom: 28. Dez., Seite 400-10  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:149  |g year:2013  |g number:3  |g day:28  |g month:12  |g pages:400-10 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2013.09.008  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 149  |j 2013  |e 3  |b 28  |c 12  |h 400-10